This biotech powerhouse could maintain its strength for the long term.

As of Wednesday, February 25, Recursion Pharmaceuticals, Inc.’s RXRX share price has surged by 11.19%, which has investors ...

Vir Biotechnology lands a license agreement with Japan’s Astellas Pharma for its lead drug candidate.

Eli Lilly continues to pursue smart acquisitions for the long term.

This player's pipeline should keep growth going over the long run.

Shares of Recursion Pharmaceuticals RXRX are surging Wednesday following a robust earnings report released before the bell. Recursion Pharmaceuticals stock is charging ahead with explosive momentum.

Tarsus Pharmaceuticals remains a Strong Buy, driven by Xdemvy's robust growth and management's $2B+ peak sales target. Click ...

Financial giants have made a conspicuous bullish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex Pharmaceuticals (NASDAQ:VRTX) revealed 35 unusual trades. Delving into the ...